A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients "EDALINE"
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
Price : $35 *
At a glance
- Drugs Sonidegib (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms EDALINE
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 09 Jun 2018 Results (n=12) published in the Investigational New Drugs.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History